Literature DB >> 27141393

The controversial role of TNF in melanoma.

Marco Donia1, Julie Westerlin Kjeldsen2, Inge Marie Svane1.   

Abstract

TNF has been associated with both inhibition and promotion of tumor growth. We recently described a mechanism by which tumor cells attract TNF producing cells via expression of MHC class II molecules.

Entities:  

Keywords:  Antitumor CD4 T cell responses; Melanoma; tumor immune escape; Tumor necrosis factor (TNF)- MHC class II

Year:  2015        PMID： 27141393      PMCID： PMC4839341          DOI： 10.1080/2162402X.2015.1107699

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.

Authors:  Marco Donia; Rikke Andersen; Julie W Kjeldsen; Paolo Fagone; Shamaila Munir; Ferdinando Nicoletti; Mads Hald Andersen; Per Thor Straten; Inge Marie Svane
Journal:  Cancer Res       Date:  2015-07-16       Impact factor: 12.701

2.  Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.

Authors:  Florie Bertrand; Julia Rochotte; Céline Colacios; Anne Montfort; Anne-Françoise Tilkin-Mariamé; Christian Touriol; Philippe Rochaix; Isabelle Lajoie-Mazenc; Nathalie Andrieu-Abadie; Thierry Levade; Hervé Benoist; Bruno Ségui
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

Review 3.  Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.

Authors:  Bharat B Aggarwal; Subash C Gupta; Ji Hye Kim
Journal:  Blood       Date:  2011-11-03       Impact factor: 22.113

4.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.

Authors:  Jennifer Landsberg; Judith Kohlmeyer; Marcel Renn; Tobias Bald; Meri Rogava; Mira Cron; Martina Fatho; Volker Lennerz; Thomas Wölfel; Michael Hölzel; Thomas Tüting
Journal:  Nature       Date:  2012-10-10       Impact factor: 49.962

Review 5.  Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype.

Authors:  Federico Garrido; Irene Romero; Natalia Aptsiauri; Angel M Garcia-Lora
Journal:  Int J Cancer       Date:  2014-12-13       Impact factor: 7.396

6.  Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma.

Authors:  Tobias Bald; Thomas Quast; Jennifer Landsberg; Meri Rogava; Nicole Glodde; Dorys Lopez-Ramos; Judith Kohlmeyer; Stefanie Riesenberg; Debby van den Boorn-Konijnenberg; Cornelia Hömig-Hölzel; Raphael Reuten; Benjamin Schadow; Heike Weighardt; Daniela Wenzel; Iris Helfrich; Dirk Schadendorf; Wilhelm Bloch; Marco E Bianchi; Claire Lugassy; Raymond L Barnhill; Manuel Koch; Bernd K Fleischmann; Irmgard Förster; Wolfgang Kastenmüller; Waldemar Kolanus; Michael Hölzel; Evelyn Gaffal; Thomas Tüting
Journal:  Nature       Date:  2014-02-26       Impact factor: 49.962

7.  A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.

Authors:  E R Brown; K A Charles; S A Hoare; R L Rye; D I Jodrell; R E Aird; R Vora; U Prabhakar; M Nakada; R E Corringham; M DeWitte; C Sturgeon; D Propper; F R Balkwill; J F Smyth
Journal:  Ann Oncol       Date:  2008-03-05       Impact factor: 32.976

8.  TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model.

Authors:  A M Waterston; F Salway; E Andreakos; D M Butler; M Feldmann; R C Coombes
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

9.  TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes.

Authors:  E Katerinaki; G S Evans; P C Lorigan; S MacNeil
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640
  9 in total
  5 in total

Review 1.  Immunoplasticity in cutaneous melanoma: beyond pure morphology.

Authors:  Francesca Maria Bosisio; Joost J van den Oord
Journal:  Virchows Arch       Date:  2017-01-05       Impact factor: 4.064

2.  Complement C3a activates astrocytes to promote medulloblastoma progression through TNF-α.

Authors:  Biao Gong; Duancheng Guo; Chaonan Zheng; Zhen Ma; Jie Zhang; Yanghui Qu; Xinhua Li; Gen Li; Li Zhang; Yuan Wang
Journal:  J Neuroinflammation       Date:  2022-06-20       Impact factor: 9.587

3.  Effects of the IL6 -174G>C promoter polymorphism and IL-6 serum levels on the progression of cutaneous malignant melanoma.

Authors:  Tatyana Vlaykova; Mateuzh Kurzawski; Tanya Tacheva; Dimo Dimov; Asen Anastasov; Denitsa Vlaykova; Ani Miteva; Niamh O'donoghue; Marek Drozdzik
Journal:  Oncol Lett       Date:  2020-06-16       Impact factor: 2.967

4.  A Multi-Omics Analysis of Metastatic Melanoma Identifies a Germinal Center-Like Tumor Microenvironment in HLA-DR-Positive Tumor Areas.

Authors:  Laura Gadeyne; Yannick Van Herck; Giorgia Milli; Zeynep Kalender Atak; Maddalena Maria Bolognesi; Jasper Wouters; Lukas Marcelis; Angeliki Minia; Vaia Pliaka; Jan Roznac; Leonidas G Alexopoulos; Giorgio Cattoretti; Oliver Bechter; Joost Van Den Oord; Frederik De Smet; Asier Antoranz; Francesca Maria Bosisio
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

Review 5.  Risk of Developing Melanoma With Systemic Agents Used to Treat Psoriasis: A Review of the Literature.

Authors:  Amy Semaka; Thomas G Salopek
Journal:  J Cutan Med Surg       Date:  2021-08-15       Impact factor: 2.092
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.